Disease Domain | Count |
---|---|
Neoplasms | 3 |
Infectious Diseases | 1 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Chemical drugs | 2 |
Small molecule drug | 1 |
mRNA vaccine | 1 |
Herbal medicine | 1 |
Biological products | 1 |
Target |
Mechanism Orexin receptor antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date20 Dec 2019 |
Target |
Mechanism PD-1 modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PDL1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jun 2024 |
Sponsor / Collaborator |
Start Date01 May 2024 |
Sponsor / Collaborator |
Start Date01 May 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Tinospora Crispa extract | Fever More | Phase 3 Clinical |
Lemborexant ( Orexin receptor ) | Sleep Apnea, Obstructive More | Phase 2 Clinical |
CU-B103 ( PDL1 ) | Colonic Cancer More | Preclinical |
CU-B206 ( PDL1 ) | Colonic Cancer More | Preclinical |
Anti PD-1 antibody(Chulalongkorn University) ( PD-1 ) | Neoplasms More | Preclinical |